UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 83 filers reported holding UROGEN PHARMA LTD in Q2 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $187,000 | -6.0% | 22,801 | 0.0% | 0.00% | +50.0% |
| Q1 2022 | $199,000 | -50.7% | 22,801 | -46.4% | 0.00% | -33.3% |
| Q4 2021 | $404,000 | -43.8% | 42,501 | 0.0% | 0.00% | -40.0% |
| Q3 2021 | $719,000 | +10.8% | 42,501 | 0.0% | 0.01% | 0.0% |
| Q2 2021 | $649,000 | -21.6% | 42,501 | 0.0% | 0.01% | -37.5% |
| Q1 2021 | $828,000 | +95.7% | 42,501 | +80.8% | 0.01% | 0.0% |
| Q4 2020 | $423,000 | -6.6% | 23,501 | 0.0% | 0.01% | -27.3% |
| Q3 2020 | $453,000 | -26.2% | 23,501 | 0.0% | 0.01% | -38.9% |
| Q2 2020 | $614,000 | +46.5% | 23,501 | 0.0% | 0.02% | -10.0% |
| Q1 2020 | $419,000 | -52.0% | 23,501 | -10.2% | 0.02% | -20.0% |
| Q4 2019 | $873,000 | +40.8% | 26,172 | 0.0% | 0.02% | +4.2% |
| Q3 2019 | $620,000 | -33.4% | 26,172 | +1.1% | 0.02% | -38.5% |
| Q2 2019 | $931,000 | +2.1% | 25,892 | +4.8% | 0.04% | -7.1% |
| Q1 2019 | $912,000 | -14.2% | 24,698 | 0.0% | 0.04% | -10.6% |
| Q4 2018 | $1,063,000 | – | 24,698 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Horton Capital Management, LLC | 684,749 | $11,517,000 | 23.27% |
| GREAT POINT PARTNERS LLC | 750,000 | $12,615,000 | 2.94% |
| HealthInvest Partners AB | 75,000 | $1,262,000 | 1.89% |
| Wildcat Capital Management, LLC | 533,139 | $8,967,000 | 1.16% |
| Annandale Capital, LLC | 86,254 | $1,451,000 | 0.87% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,954,699 | $49,698,000 | 0.73% |
| ZEKE CAPITAL ADVISORS, LLC | 723,677 | $12,172,000 | 0.70% |
| Yahav Achim Ve Achayot - Provident Funds Management Co Ltd. | 25,330 | $426,000 | 0.34% |
| RTW INVESTMENTS, LP | 857,464 | $14,423,000 | 0.22% |
| SHIKIAR ASSET MANAGEMENT INC | 33,350 | $561,000 | 0.16% |